June 03, 2021 Asco 2021 justifies Novartis’s radioligand Vision 177Lu-PSMA-617 shows impressive survival results in the Vision study, but early use will be key to fulfilling its potential.
March 31, 2021 Radiotherapeutics remain in the deal-making frame A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
